ES2656091T3 - Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan - Google Patents

Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan Download PDF

Info

Publication number
ES2656091T3
ES2656091T3 ES13745549.9T ES13745549T ES2656091T3 ES 2656091 T3 ES2656091 T3 ES 2656091T3 ES 13745549 T ES13745549 T ES 13745549T ES 2656091 T3 ES2656091 T3 ES 2656091T3
Authority
ES
Spain
Prior art keywords
approximately
elacridar
composition
hydrochloride
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13745549.9T
Other languages
English (en)
Spanish (es)
Inventor
Olaf Van Tellingen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Izumi Tech LLC
Izumi Technology LLC
Original Assignee
Izumi Tech LLC
Izumi Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Izumi Tech LLC, Izumi Technology LLC filed Critical Izumi Tech LLC
Application granted granted Critical
Publication of ES2656091T3 publication Critical patent/ES2656091T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13745549.9T 2012-07-27 2013-07-26 Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan Active ES2656091T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676689P 2012-07-27 2012-07-27
US201261676689P 2012-07-27
PCT/US2013/052402 WO2014018932A2 (en) 2012-07-27 2013-07-26 Effluz inhibitor compositions and methods of treatment using the same

Publications (1)

Publication Number Publication Date
ES2656091T3 true ES2656091T3 (es) 2018-02-23

Family

ID=48917738

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13745549.9T Active ES2656091T3 (es) 2012-07-27 2013-07-26 Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan

Country Status (11)

Country Link
US (4) US20140235631A1 (enExample)
EP (1) EP2877159B8 (enExample)
JP (1) JP6464084B2 (enExample)
CN (1) CN104736144B (enExample)
AU (1) AU2013295549B2 (enExample)
BR (1) BR112015001838B1 (enExample)
CA (1) CA2880236C (enExample)
ES (1) ES2656091T3 (enExample)
IN (1) IN2015MN00408A (enExample)
MX (1) MX379717B (enExample)
WO (1) WO2014018932A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US11147809B2 (en) 2010-08-27 2021-10-19 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
WO2018005994A1 (en) * 2016-07-01 2018-01-04 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
MX375442B (es) 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150095055A1 (en) * 2013-09-30 2015-04-02 Horizon Pharma Usa, Inc. Methods for processing a prescription drug request
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104352632B (zh) * 2014-11-12 2017-11-24 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为肝转运体抑制剂的应用
WO2016080846A1 (en) * 2014-11-17 2016-05-26 Janine Naomi Copp Antibacterial compounds
WO2016090240A1 (en) * 2014-12-04 2016-06-09 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
CN104784179A (zh) * 2015-04-01 2015-07-22 重庆理工大学 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物
KR101778004B1 (ko) * 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11110172B2 (en) 2016-04-08 2021-09-07 Imam Abdulrahman Bin Faisal University Method for treating multiloculated hydrocephalus by administering an anti-IL6 receptor antibody
WO2017192942A1 (en) * 2016-05-06 2017-11-09 THE USA, as representd by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES Methods for improving drug delivery across a p-glycoprotein expressing barrier
CN107397721B (zh) * 2016-05-18 2019-01-22 中国医学科学院基础医学研究所 含有布比卡因的药物组合物及其制备方法和用途
WO2017214468A1 (en) * 2016-06-09 2017-12-14 Tien Yang Der Nanodroplet compositions for the efficient delivery of anti-cancer agents
CA3027368A1 (en) * 2016-06-13 2017-12-21 Ascendia Pharmaceuticals, Llc Parenteral sustained-release delivery of carvedilol disperse systems
EP3478364B1 (en) * 2016-07-01 2024-11-13 Dignity Health Diagnostic or predictor of relapsing remitting multiple sclerosis
WO2018118910A1 (en) * 2016-12-22 2018-06-28 Academia Sinica Dipyridamole for use in treating slc29a2 nuclear-expressing cancer
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018204829A1 (en) * 2017-05-04 2018-11-08 University Of Maryland, Baltimore Methods for preventing neural tube defects in diabetic pregnancy
US11504362B2 (en) 2017-06-09 2022-11-22 Exelixis, Inc. Liquid dosage forms to treat cancer
US20190038624A1 (en) * 2017-08-03 2019-02-07 Daniel Dung Truong Use of abelson tyrosine kinase inhibitor in treatment of multiple system atrophy
US20200390717A1 (en) * 2017-11-21 2020-12-17 University Of Iowa Research Foundation Synthetically lethal nanoparticles for treatment of cancers
US11433021B2 (en) 2018-01-12 2022-09-06 Orion Corporation Palonosetron for the treatment or prevention of nausea and vomiting
JP7436375B2 (ja) * 2018-03-21 2024-02-21 イズミ テクノロジー，エルエルシー エラクリダールの重水素化類似体
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
CN108484751B (zh) * 2018-04-19 2020-06-23 西南大学 川陈皮素抗原及其制备方法与应用
CN109111533B (zh) * 2018-05-10 2020-05-08 上海交通大学 硫酸肝素与fk506共轭物酶化学合成以及应用
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
CN108670950B (zh) * 2018-06-29 2020-10-02 深圳海王医药科技研究院有限公司 一种不含有机溶剂的虎杖苷药物组合物及其制备方法
CN108808030B (zh) * 2018-07-03 2023-08-08 重庆大学 基于b-z振荡反应的脉冲电池设计
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
TWI816881B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 用於治療三陰性乳癌之組合療法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN111617258A (zh) * 2019-02-28 2020-09-04 江苏恒瑞医药股份有限公司 一种制备阿比特龙或其衍生物药物组合物的方法及其应用
CN110498784B (zh) * 2019-05-20 2022-06-14 广东克冠达医药科技有限公司 一类川陈皮素衍生物或其药学上可接受的盐及其制备方法和应用
CN111296417B (zh) * 2020-04-01 2021-04-20 广东省农业科学院植物保护研究所 一种星·甲维悬浮剂及其制备方法与应用
JP2023533911A (ja) * 2020-07-10 2023-08-07 チャン グァン メモリアル ホスピタル，リンコウ 上皮成長因子受容体阻害剤によって誘発される上皮細胞損傷を軽減し及び癌細胞を阻害する組成物の製造のための、β－１アドレナリン受容体アンタゴニストの使用
WO2022020114A2 (en) * 2020-07-10 2022-01-27 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
CN111840255B (zh) * 2020-07-31 2022-03-01 北京丰帆生物医药科技有限公司 一种维拉帕米温敏缓释制剂及其制备方法和应用
KR102444571B1 (ko) * 2020-11-18 2022-09-19 주식회사태준제약 세티리진 및 토코페솔란을 포함하는 안과용 조성물
CN113384702A (zh) * 2021-05-20 2021-09-14 温州医科大学附属第一医院 H1组胺受体拮抗剂在制备治疗神经胶质瘤的药物中的应用
WO2023014361A1 (en) * 2021-08-05 2023-02-09 La Pharma Tech Inc. Novel pharmaceutical compositions and methods for treatment of psychiatric disorders
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品
TW202423434A (zh) * 2022-10-07 2024-06-16 瑞士商歐庫利斯營運股份有限公司 mTOR抑制劑的點眼劑微懸液
CN115779089A (zh) * 2022-11-28 2023-03-14 中国医学科学院肿瘤医院 用于治疗或改善雄性癌症及抑制其细胞系的药物的相关应用
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법
CN116919968A (zh) * 2023-08-14 2023-10-24 上海交通大学医学院附属第九人民医院 磷酸芦可替尼在制备促进皮肤创面愈合的药物中的用途
WO2025213381A1 (en) * 2024-04-10 2025-10-16 Hangzhou Jitai Pharmaceutical Technology Co., Ltd Neratinib-cyclodextrin composition and method for preparing same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2366932C (en) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PL209733B1 (pl) 2000-10-27 2011-10-31 Novartis Ag Zastosowanie 4-(4-metylopiperazyno-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]benzamidu w leczeniu żołądkowo-jelitowych guzów podścieliskowych
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1896831B1 (en) * 2005-06-27 2013-04-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES A spatially selective, fixed-optics multicolor fluorescence detection system for a multichannel microfluidic device, and method for detection
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
WO2008066899A2 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer

Also Published As

Publication number Publication date
MX2015001194A (es) 2015-11-23
BR112015001838B1 (pt) 2022-10-25
AU2013295549A1 (en) 2015-03-19
CN104736144B (zh) 2019-02-01
US20140235631A1 (en) 2014-08-21
CA2880236C (en) 2022-09-13
CA2880236A1 (en) 2014-01-30
US20200405683A1 (en) 2020-12-31
US20190167630A1 (en) 2019-06-06
MX379717B (es) 2025-03-11
WO2014018932A3 (en) 2014-03-20
AU2013295549B2 (en) 2018-04-19
HK1210957A1 (en) 2016-05-13
JP6464084B2 (ja) 2019-02-06
WO2014018932A2 (en) 2014-01-30
WO2014018932A8 (en) 2014-12-31
IN2015MN00408A (enExample) 2015-09-04
BR112015001838A2 (pt) 2017-07-04
US20220133679A1 (en) 2022-05-05
JP2015523400A (ja) 2015-08-13
EP2877159B1 (en) 2017-11-08
CN104736144A (zh) 2015-06-24
EP2877159A2 (en) 2015-06-03
EP2877159B8 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
US20220133679A1 (en) Efflux inhibitor compositions and methods of treatment using the same
US10561650B2 (en) Method for treating a protozoal infection
JP4860469B2 (ja) 新規シルデナフィル遊離塩基組成物
ES2952025T3 (es) Una formulación de rapamicina inhalable para tratar condiciones relacionadas con la edad
JP4787165B2 (ja) 表面安定剤としてペプチドを有するナノ粒子組成物
JP4469846B2 (ja) ナノ粒子状トピラメート製剤
CA2862689C (en) .alpha.-methyl-dl-tyrosine, compositions, kits, combinations and use thereof for the treatment of cancer or for reducing cell proliferation
US20230240997A1 (en) Method of treating cancer
EA013741B1 (ru) Дисперсии наночастиц такролимуса с повышенными растворимостью в воде и биодоступностью, способы их приготовления и применения
MX2007015309A (es) Formulaciones de mesilato de imatinib en nanoparticulas.
JP2020528928A (ja) ジピベフリンの使用方法
US20210213051A1 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
JP2018199685A (ja) インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
JP2022153587A (ja) チロシン誘導体及びそれらを含む組成物
US10272068B2 (en) Pharmaceutical compositions and methods
JP2022553175A (ja) がんの処置における使用のためのα－メチル－ＤＬ－チロシンのアルキルエステル
Mukhopadhyay Nano drugs: A critical review of their patents and market
US20240277756A1 (en) Silicon particles for hydrogen release
JP2016513694A (ja) ビタミンｂ１２欠乏症を治療する方法
HK1210957B (en) Efflux inhibitor compositions and methods of treatment using the same
JP7508123B2 (ja) 吸入化学療法用キットおよび当該キットによる肺癌の処置
JP2017525658A (ja) ニコチンと酸化セリウムとのナノ粒子複合体及びその使用